A sensitive venous bleeding model in haemophilia A mice: Effects of two recombinant FVIII products (N8 and Advate®)

Haemophilia

Volumn 18, Issue 5, 2012, Pages 782-788

  Pastoft, A E ^a,b   Lykkesfeldt, J ^a   Ezban, M ^b   Tranholm, M ^b   Whinna, H C ^c   Lauritzen, B ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bleeding model; Factor VIII; Haemophilia A; Vena saphena injury

Indexed keywords

N 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEMOPHILIA A; HEMOSTASIS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SAPHENOUS VEIN; SENSITIVE VENOUS BLEEDING;

ANIMALS; BLEEDING TIME; DISEASE MODELS, ANIMAL; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT PROTEINS; SAPHENOUS VEIN;

EID: 84865552831     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02780.x     Document Type: Article

References (39)

1. White GC, Rosendaal F, Aledort LM et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2000; 85: 560-2001.
2. Collins PW, Björkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
3. Berntorp E. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. Baillieres Clin Haematol 1996; 9: 259-71.
4. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-98.
5. Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-97.
6. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
7. Bi L, Sarkar R, Naas T et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
8. Muchitsch EM, Turecek PL, Zimmermann K et al. Phenotypic expression of murine hemophilia. Thromb Haemost 1999; 82: 1371-3.
9. Tsakiris DA, Scudder L, Hodivala-Dilke K, Hynes RO, Coller BS. Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost 1999; 81: 177-88.
10. Baumgartner B, Jaki T, Wolfsegger MJ et al. Optimization, refinement and reduction of murine in vivo experiments to assess therapeutic approaches for haemophilia A. Lab Anim 2010; 44: 211-7.
11. Broze GJ, Yin ZF, Lasky N. A tail vein bleeding time model and delayed bleeding in hemophiliac mice. Thromb Haemost 2001; 85: 747-8.
12. Jesmok J. Comparison of Human and Murine rFVIII in a Standardized FVIII Dependent Bleed Model in FVIII -/- Mice. Cui Z-H, Canivel D, Lollar P, Parker ET, Landskroner KA, editors. J Thromb Haemost 2007; 5(Suppl 2): P-M-030.
13. Parker ET, Lollar P. A quantitative measure of the efficacy of factor VIII in hemophilia A mice. Thromb Haemost 2003; 89: 480-5.
14. Møller F, Tranholm M. A ferric chloride induced arterial injury model used as haemostatic effect model. Haemophilia 2010; 16: e216-22.
15. Wang X, Cheng Q, Xu L et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3: 695-702.
16. Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004; 10: 280-7.
17. Ovlisen K, Kristensen AT, Valentino LA, Hakobyan N, Ingerslev J, Tranholm M. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice. J Thromb Haemost 2008; 6: 969-75.
18. Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
19. Saenko EL, Pipe SW. Strategies towards a longer acting factor VIII. Haemophilia 2006; 12(Suppl 3): 42-51.
20. Buyue Y, Whinna HC, Sheehan JP. The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis. Blood 2008; 112: 3234-41.
21. Whinna HC, Monroe DM. A novel murine hemostasis model: studies on recombinant factor VIIa and NN1731. J Thromb Haemost 2009; 7: PP-MO-379, Abstract.
22. Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost 2009; 7: 651-7.
23. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
24. Christiansen ML, Balling KW, Persson E et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878-87.
25. Holmberg HL, Lauritzen B, Tranholm M, Ezban M. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 2009; 7: 1517-22.
26. Karpf DM, Kjalke M, Thim L et al. Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs. Haemophilia 2011; 17: e963-8.
27. Martinowitz U, Bjerre J, Brand B et al. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 2011; 17: 854-9.
28. Thim L, Vandahl B, Karlsson J et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010; 16: 349-59.
29. Elm T, Karpf DM, Ovlisen K et al. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. Haemophilia 2012; 18: 139-45.
30. Pan J, Liu T, Kim JY et al. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice. Blood 2009; 114: 2802-11.
31. Greene TK, Schiviz A, Hoellriegl W, Poncz M, Muchitsch EM, -Animal MSotSASCOTI. Towards a standardization of the murine tail bleeding model. J Thromb Haemost 2010; 8: 2820-2.
32. Dejana E, Villa S, De Gaetano G. Bleeding time in rats: a comparison of different experimental conditions. Thromb Haemost 1982; 48: 108-11.
33. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002; 8: 1175-81.
34. Neyman M, Gewirtz J, Poncz M. Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII based clots. Blood 2008; 112: 1101-8.
35. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
36. Wang X, Xu L. An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb Res 2005; 115: 95-100.
37. Rodriguez-Merchan EC. Effects of hemophilia on articulations of children and adults. Clin Orthop Relat Res 1996; 328: 7-13.
38. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12(Suppl 3): 117-21.
39. Valentino LA, Hakobyan N, Kazarian T, Sorensen BB, Tranholm M. Prevention of haemarthrosis in a murine model of acute joint bleeding. Haemophilia 2009; 15: 314-9.